Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Ilant Health vs Teleios Health

Ilant Health
Graded #407

Lower grade

vs+3.4000000000000057
Teleios Health
Graded #327

Higher grade

The verdict

Teleios Health takes it — 60.2/100 to 56.8/100.

Teleios Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Teleios Health is a physician-led, cash-pay GLP-1 weight-loss platform marketing compounded semaglutide from $99/mo and compounded tirzepatide from $139/mo, delivered direct to your door through a fully…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueTeleios Health +39
45
84
Dose & formulationTeleios Health +24
40
64
Clinical oversightIlant Health +34
83
49
Labs & monitoringIlant Health +13
61
48
FulfillmentIlant Health +20
62
42
Contract termsEven
55
55
Ilant Health · left barTeleios Health · right bar

The numbers

MetricIlant HealthTeleios Health
WeighScore56.8/10060.2/100
GradeCC
Scorecard rank#407#327
SemaglutideNot disclosed$99/mo (starting dose, compounded)
TirzepatideNot disclosed$139/mo (starting dose, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Ilant Health

Graded #407 · C

Strengths

  • Value-based, outcomes-driven obesity care model
  • Includes GLP-1 medications with transparent drug pricing for sponsors
  • Care team of board-certified obesity providers and behavioral specialists
  • Dietitians and peer navigators support adherence
  • Data-driven stratification targets the right interventions

Where it loses points

  • Distributed via employers and health plans, not direct cash-pay
  • Individuals generally cannot enroll without sponsor coverage
  • No public consumer pricing for GLP-1
  • Access gated behind organizational buyers
  • Not suited to consumers wanting direct-to-door GLP-1
Teleios Health

Graded #327 · C

Strengths

  • Compounded semaglutide from $99/mo — among the lowest floor prices in cash-pay telehealth
  • Compounded tirzepatide from a competitive $139/mo floor
  • Markets physician (MD/DO) prescribing rather than an NP-only model
  • Clean meta-tag and SEO implementation

Where it loses points

  • Single-page app: state availability, pharmacy partner, dose pricing, lab requirements, and refund policy aren't visible and couldn't be verified
  • No named medical director, physician, or corporate entity disclosed
  • Year founded unknown — a newer floor-price entrant warranting extra scrutiny
  • No LegitScript, NABP, or SOC 2 trust signal found
  • Heavy paid-acquisition ad-tech stack — pair with diligence on the clinical layer

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard